Skip to main content

Market Overview

Markets
QQQ561.45
-0.35-0.06%
DIA443.31
-1.91-0.43%
SPY627.90
-0.14-0.02%
TLT85.38
+0.270.32%
GLD308.82
+1.230.40%

Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing

Share:
Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing

Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)’s approach to healthcare pricing.

Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren’s healthcare pricing strategy. They criticized the senator for not addressing the role of pharmacy benefit managers (PBMs) in escalating drug costs.

Warren had previously argued that the tax system was “rigged” because large pharmaceutical companies like Johnson & Johnson (NYSE:JNJ) often escape federal taxes while charging exorbitant prices for their drugs.

She wrote on X saying that the "highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves."

Live Sunday: Matt Maley’s Volatility Trading Plan for Earnings, Tariffs, & the Fed

Three big catalysts are gearing up to hit the markets at month’s end. Matt Maley is going live this Sunday at 1 PM ET to reveal how he’s trading short-term setups across financials, tech, defense, and more. If you’re watching earnings, tariff drama, or Fed risk—this is your moment to act. Secure your free seat here.


Cuban countered this by stating that PBMs, not pharmaceutical companies, are the ones controlling and manipulating drug pricing.

Also Read: Cuban on Musk: ‘I Have No Problem Throwing Elon Under the Bus, but I’ll Save It for When It’s Truly Deserved’

Trump Jr. publicly supported Cuban’s viewpoint on X, despite Cuban’s well-known opposition to President Trump. This unexpected agreement highlights the growing concern over the role of PBMs in healthcare pricing.


PBMs have been facing increasing scrutiny from federal regulators and lawmakers due to their influence on healthcare pricing.

In 2020, the Federal Trade Commission released a report criticizing PBMs for imposing unfair terms on independent pharmacies, thereby favoring large corporate pharmacies like CVS (NYSE:CVS).

The public criticism from Trump Jr. and Cuban underscores the growing debate over the role of PBMs in healthcare pricing.

Warren’s focus on pharmaceutical companies, while not entirely misplaced, overlooks the significant influence of PBMs in determining drug prices.

The Federal Trade Commission’s report from last year further highlights the need for regulatory scrutiny of PBMs. As the debate continues, it remains to be seen how lawmakers will address the issue of healthcare pricing and the role of PBMs in the future.

Read Next

Mark Cuban Reacts to Elon Musk-Donald Trump Feud

Image: Shutterstock/lev radin

The 10X Strategy Revealed - Free Live Event Wednesday

Professional investors don't guess which stocks will explode - they use proven systems to identify them early. See Tim Melvin's 35-year approach plus Anne-Marie Baiynd's strategies for maximizing returns. Live collaboration for the first time ever. [Register Free]

 

Related Articles (CVS + JNJ)

View Comments and Join the Discussion!

Posted-In: Donald Trump Jr Elizabeth Warren Mark Cuban pharmaNews Politics Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com